All Stories

  1. Examination of multiple Trypanosoma cruzi targets in a new drug discovery approach for Chagas disease
  2. Advances in Drug Discovery against Neglected Tropical Diseases: Human African and American Trypanosomiasis
  3. Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease
  4. Selenium as an interesting option for the treatment of Chagas disease: A review
  5. The role of imidazole and benzimidazole heterocycles in Chagas disease: A review
  6. Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation
  7. Antichagasic profile of a Series of Mannich Base‐Type Derivatives: Design, Synthesis, in vitro Evaluation, and Computational Studies Involving Iron Superoxide Dismutase
  8. A step towards development of promising trypanocidal agents: Synthesis, characterization and in vitro biological evaluation of ferrocenyl Mannich base-type derivatives
  9. Organometallic compounds in the discovery of new agents against kinetoplastid-caused diseases
  10. Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi
  11. Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity
  12. Development, validation and application of a GC–MS method for the simultaneous detection and quantification of neutral lipid species in Trypanosoma cruzi
  13. Aantileishmanial activity of arylamine Mannich base derivatives
  14. Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease
  15. Library of Seleno-Compounds as Novel Agents against Leishmania Species
  16. A Comparative Study of Conventional and Microwave-Assisted Synthesis of Quinoxaline 1,4-di-N-oxideN-acylhydrazones Derivatives Designed as Antitubercular Drug Candidates
  17. Correction to In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives
  18. In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives
  19. Exploring the scope of new arylamino alcohol derivatives: Synthesis, antimalarial evaluation, toxicological studies, and target exploration
  20. Challenges in Chagas Disease Drug Discovery: A Review
  21. Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis
  22. Synthesis and biological evaluation of quinoxaline di- N -oxide derivatives with in vitro trypanocidal activity
  23. Synthesis, Biological Evaluation and Structure-Activity Relationships of New Quinoxaline Derivatives as Anti-Plasmodium falciparum Agents
  24. Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents
  25. New Amide Derivatives of Quinoxaline 1,4-di-N-Oxide with Leishmanicidal and Antiplasmodial Activities
  26. Antiplasmodial and Leishmanicidal Activities of 2-Cyano-3-(4-phenylpiperazine-1-carboxamido) Quinoxaline 1,4-Dioxide Derivatives
  27. New Quinoxaline Derivatives as Potential MT1 and MT2 Receptor Ligands
  28. Novel sulfonylurea derivatives as H3 receptor antagonists. Preliminary SAR studies
  29. Studies on Log Po/w of Quinoxaline di-N-Oxides: A Comparison of RP-HPLC Experimental and Predictive Approaches
  30. New salicylamide and sulfonamide derivatives of quinoxaline 1,4-di-N-oxide with antileishmanial and antimalarial activities
  31. Aryl piperazine and pyrrolidine as antimalarial agents. Synthesis and investigation of structure–activity relationships
  32. New 1,4-di-N-oxide-quinoxaline-2-ylmethylene isonicotinic acid hydrazide derivatives as anti-Mycobacterium tuberculosis agents
  33. 3-TrifluoromethylquinoxalineN,N′-Dioxides as Anti-Trypanosomatid Agents. Identification of Optimal Anti-T. cruziAgents and Mechanism of Action Studies
  34. Novel Benzo[b]thiophene Derivatives as New Potential Antidepressants with Rapid Onset of Action
  35. Trypanocidal properties, structure–activity relationship and computational studies of quinoxaline 1,4-di-N-oxide derivatives
  36. 1,4-Di-N-oxide quinoxaline-2-carboxamide: Cyclic voltammetry and relationship between electrochemical behavior, structure and anti-tuberculosis activity
  37. Synthesis and Biological Evaluation of New Quinoxaline Derivatives as Antioxidant and Anti-Inflammatory Agents
  38. Building a MCHR1 homology model provides insight into the receptor–antagonist contacts that are important for the development of new anti-obesity agents
  39. Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives
  40. New 3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents
  41. New 1-Aryl-3-Substituted Propanol Derivatives as Antimalarial Agents
  42. Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs
  43. Selective activity against Mycobacterium tuberculosis of new quinoxaline 1,4-di-N-oxides
  44. Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates
  45. Synthesis and structure–activity relationship of 3-phenylquinoxaline 1,4-di-N-oxide derivatives as antimalarial agents
  46. Efficacy of Quinoxaline-2-Carboxylate 1,4-Di-N-Oxide Derivatives in Experimental Tuberculosis
  47. In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide
  48. Melanin-Concentrating Hormone Receptor 1 Antagonists: A New Perspective for the Pharmacologic Treatment of Obesity
  49. Substitutions of Fluorine Atoms and Phenoxy Groups in the Synthesis of Quinoxaline 1,4-di-N-oxide Derivatives
  50. Synthesis and Antiplasmodial Activity of 3-Furyl and 3-Thienylquinoxaline-2-carbonitrile 1,4-Di-N-oxide Derivatives
  51. Unexpected Reduction of Ethyl 3-Phenylquinoxaline-2- carboxylate 1,4-Di-N-oxide Derivatives by Amines
  52. Antiplasmodial structure–activity relationship of 3-trifluoromethyl-2-arylcarbonylquinoxaline 1,4-di-N-oxide derivatives
  53. Synthesis and anti-inflammatory/antioxidant activities of some new ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives and of their 4,5-dihydro-(1H)-pyrazole analogues
  54. Synthesis and Biological Evaluation of New 2-Arylcarbonyl-3-trifluoromethylquinoxaline 1,4-Di-N-oxide Derivatives and Their Reduced Analogues
  55. Novel series of substituted biphenylmethyl urea derivatives as MCH-R1 antagonists for the treatment of obesity
  56. Synthesis and evaluation of new hydrazide derivatives as neuropeptide Y Y5 receptor antagonists for the treatment of obesity
  57. Synthesis of new thiophene and benzo[b]thiophene hydrazide derivatives as human NPY Y5 antagonists
  58. Synthesis and evaluation of new arylsulfonamidomethylcyclohexyl derivatives as human neuropeptide Y Y5 receptor antagonists for the treatment of obesity
  59. Synthesis and Molecular Modeling of New 1-Aryl-3-[4-arylpiperazin-1-yl]-1-propane Derivatives with High Affinity at the Serotonin Transporter and at 5-HT1AReceptors
  60. New 1-Aryl-3-(4-arylpiperazin-1-yl)propane Derivatives, with Dual Action at 5-HT1ASerotonin Receptors and Serotonin Transporter, as a New Class of Antidepressants
  61. New 3-[4-(aryl)piperazin-1-yl]-1-(benzo[b]thiophen-3-yl)propane derivatives with dual action at 5-HT1A serotonin receptors and serotonin transporter as a new class of antidepressants
  62. Design, synthesis and biological evaluation of new 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives as potential antidepressants with a dual mode of action: serotonin reuptake inhibition and 5-HT1A receptor antagonism